Business
Sierra Oncology host KOL Meeting on 12 Oct in NY
Sierra Oncology host KOL Meeting on 12 Oct in NY.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 0604T Sareum Holdings PLC 09 October 2017 \n\n\n\n\n\n (AIM: SAR)\n\n\n9 October 2017\n\n\n\n\nSAREUM HOLDINGS PLC\n(\"Sareum\" or \"the Company\")\nSierra Oncology to host Key Opinion Leader Meeting \"Beyond PARP: The Clinical Potential of Next Generation DNA Damage Response (DDR) Therapeutics\" on October 12th in NY \nSareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, notes that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, will host a Key Opinion Leader (KOL) luncheon on the topic of \"Beyond PARP: The Clinical Potential of Next Generation DNA Damage Response Therapeutics\" on Thursday, October 12 from 12:00-13:30hrs EST in New York, USA. \nThe meeting will feature presentations by three KOLs in DDR scientific and clinical development: \n• Leonard Post, PhD, Chief Scientific Officer of Vivace Therapeutics; former CSO of BioMarin Pharmaceutical, will discuss lessons learned from PARP inhibitor development, with a focus on optimizing drug properties; \n• Eric J. Brown, PhD, Associate Professor of Cancer Biology at the Perelman School of Medicine of the University of Pennsylvania, will discuss the ATR/Chk1 pathway and its biology, highlighting emerging views on the importance of replication stress; \n• Geoffrey I. Shapiro, MD, PhD, Associate Professor of Medicine at Harvard Medical School; Clinical Director at the Center for DNA Damage and Repair, and Director of the Early Drug Development Center at Dana-Farber Cancer Institute, will discuss translating emerging DDR science into the cancer clinic, emphasizing the importance of patient selection strategies.\nIn addition to the KOL presentations, Dr. Nick Glover, President and CEO of Sierra Oncology, will provide a brief overview on the company's ongoing clinical development program for SRA737, a potent, highly selective, orally bioavailable small molecule inhibitor of the emerging DDR target, Chk1. \nFollowing the presentation, the KOLs, along with members of Sierra's Senior Management team, will be available to answer questions. \nA live webcast of the event and...